# Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

> **NCT03562377** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 215 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Placebo
- **BIOLOGICAL:** Tdap vaccine
- **BIOLOGICAL:** Meningococcal vaccine

## Key facts

- **NCT ID:** NCT03562377
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-13
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-11-22
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562377, "Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03562377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*